Brief: Maze Therapeutics Announces Positive First-In-Human Results From Phase 1 Trial Of Mze782
11/09/2025 12:39
Sept 11 (Reuters) - Maze Therapeutics Inc MAZE.O: MAZE THERAPEUTICS ANNOUNCES POSITIVE FIRST-IN-HUMAN RESULTS FROM PHASE 1 TRIAL OF MZE782, ESTABLISHING PROOF OF MECHANISM FOR A POTENT, ORAL SLC6A19 INHIBITOR WITH POTENTIAL TO TREAT PHENYLKETONURIA (PKU) AND CHRONIC KIDNEY DISEASE (CKD) MAZE THERAPEUTICS INC - WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS OBSERVED MAZE THERAPEUTICS INC - PHASE 2 TRIALS FOR PKU AND CKD EXPECTED IN 2026 MAZE THERAPEUTICS INC - 42-FOLD INCREASE IN URINARY PHENYLALANINE EXCRETION OBSERVED IN FROM PHASE 1 TRIAL OF MZE782 Source text: ID:nGNX5LNFsP Further company coverage: MAZE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maze Therapeutics
See all newsMaze Therapeutics rises after Citi initiates with 'buy'
Maze Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Maze Therapeutics Q2 net loss widens, misses estimates on higher R&D expenses
Maze Therapeutics posts smaller than expected Q1 loss
U.S. STOCKS ON THE MOVE-Tesla, AT&T, Yesway